Navigation Links
Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
Date:5/31/2012

RARITAN, N.J., May 31, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of canagliflozin, an investigational, oral, once-daily, selective sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes.

The kidneys of people with type 2 diabetes reabsorb greater amounts of glucose back into the body compared to non-diabetic people, which may contribute to elevated glucose levels. Canagliflozin blocks the reabsorption of glucose by the kidney, increasing glucose excretion and lowering blood glucose levels.

The filing is supported by a comprehensive global Phase 3 clinical development program, which included nine multicenter, randomized clinical studies that enrolled approximately 10,300 patients, representing the largest late-stage development program for an investigational pharmacologic product for the treatment of patients with type 2 diabetes submitted to health authorities to date. The Phase 3 program evaluated the safety and efficacy of canagliflozin across the spectrum of type 2 diabetes and included placebo- and active comparator-controlled studies. The program also included a dedicated cardiovascular study conducted in patients who have or are at high risk for developing cardiovascular disease. Janssen will present data from the Phase 3 studies at future scientific venues, beginning with the Scientific Sessions of the American Diabetes Association in Philadelphia, in June.

Janssen and its affiliates have rights to canagliflozin through a license agreement with Mitsubishi Tanabe Pharma Corporation. Janssen Pharmaceuticals, Inc. has marketing rights in North America, South America, Europe, Middle East, Africa, Australia, New Zealand and parts of Asia.

About Type 2 Diabetes

Type 2 diabetes is a chronic co
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
2. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
3. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season
4. Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research
5. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
6. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit
7. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
8. The Pittsburgh Life Sciences Greenhouse Congratulates Diamyd Medical on Its Agreement with Ortho-McNeil-Janssen Pharmaceuticals to Develop Diabetes Therapy
9. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT
10. Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations
11. Lilly Makes an Irrevocable Offer to Acquire Janssen Animal Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 Amgen (NASDAQ: ... quarter of 2014. Key results include: , Total ... percent product sales growth driven by strong performance across ... (carfilzomib), Prolia ® (denosumab) and XGEVA ® ... to $2.37, driven by higher revenues and a significant ...
(Date:7/29/2014)... BASKING RIDGE, N.J. , July 29, 2014 /PRNewswire/ ... a biopharmaceutical company focused on the Phase 3 clinical ... first-in-class, actively controllable antithrombotic drug system, today announced that ... webcast on Tuesday, Aug. 12, 2014, at 8:30 a.m. ... and corporate highlights. Interested participants and investors ...
(Date:7/29/2014)... Minn. , July 29, 2014  EnteroMedics Inc. ... devices using neuroblocking technology to treat obesity, metabolic diseases ... host a conference call on Thursday, August 7, 2014 ... for the second quarter ended June 30, 2014 and ... Details The second quarter conference call may ...
Breaking Medicine Technology:Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3
... 24, 2012 Marking a major milestone for ... a developer of oral drug delivery systems, announced today that ... Australian Patent Office. The patent covers an important part of ... of peptides. Oramed,s portfolio now consists of one issued patent ...
... Jan. 24, 2012  LoneStar Heart Inc., based here, today ... and Mark Maciejewski to the company,s board of directors. ... the board for LoneStar Heart; Frank Ahmann, the company,s ... executive officer of Vessix Vascular, Inc.; and Eric N. ...
Cached Medicine Technology:Oramed Pharmaceuticals Granted Australian Patent for Important Part of the Company's Core Technology in Oral Delivery of Proteins 2LoneStar Heart Inc. Names Andrew J. Coats, M.D., and Mark Maciejewski to Its Board of Directors 2LoneStar Heart Inc. Names Andrew J. Coats, M.D., and Mark Maciejewski to Its Board of Directors 3
(Date:7/30/2014)... According to the Yeast Infection No More book review ... will help candida sufferers get rid of their yeast ... to readers the truth about yeast infection and the real ... will discover natural and safe remedies to relieve symptoms of ... irritation of the vagina or vulva. , Vkool reveals ...
(Date:7/30/2014)... Seattle, WA (PRWEB) July 30, 2014 According ... by Vkool.com, this is a comprehensive bodybuilding guide for men ... press by up to 50 pounds in within a ... routine that will help keep their shoulders healthy and avoid ... that the Critical Bench Program 2.0 uncovers to learners the ...
(Date:7/30/2014)... Kennewick, WA (PRWEB) July 30, 2014 ... today availability of over 80 different electronic therapy ... notes on tablets and other computing devices all ... 80+ therapy notes or electronic medial records (EMR) ... initial evaluations, and other essential categories. SOAP ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 pMD, ... physician communication, launched an Observation Result (ORU) interface ... hospital. pMD’s cardiology customers are using the ORU ... for their test interpretations for electrocardiograms, echocardiograms, and ... in the hospital, the cardiology system produces electronic ...
(Date:7/30/2014)... TN (PRWEB) July 30, 2014 Regents ... medical imaging services, has brought health care industry veteran ... on board to help lead the company’s ambitious plans ... , “Regents Health has been moving along at a ... to kick it up a notch,” says Bob Maier, ...
Breaking Medicine News(10 mins):Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 2Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 3Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 2Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 3Health News:My Clients Plus Announces Over 80 Online Therapy Notes to Help Healthcare Providers Go Paperless 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 3Health News:Sferrella and Demonbreun Join Regents Health Resources 2
... Nov. 27 S*BIO Pte Ltd today announced ... development,candidate, SB1317. This is a novel orally-available small ... SB1317 is designed to selectively inhibit major ... progression in acute,leukemias. Flt3 mutations are the most ...
... NEWTOWN SQUARE, Pa., Nov. 27 In its ... homeopathy, Boiron,Laboratories disputes an editorial comment published in ... that its author has misinterpreted results of,clinical trials ... journal features an editorial by Ben Goldacre on,the ...
... reflect reports of bizarre behaviors and sudden deaths ... U.S. Food and Drug Administration advisory panel recommended Tuesday ... a stronger warning label to reflect reports of bizarre ... , The FDA,s Pediatric Advisory Committee, in a 9-5 ...
... Nov. 27 Zimmer Holdings, Inc.,(NYSE: ZMH ; ... resign,as Chairman of the Board and a member of ... years of service with the Company. John L.,McGoldrick, a ... Mr. Elliott served as Chairman, President and Chief Executive ...
... Pronounced "mursa,",methicillin-resistant staphylococcus aureus (MRSA) is one of ... about it. It has,killed the elderly, babies, toddlers, teenagers ... closing public schools., One of the most common ... infection can start innocently, perhaps with a nick or ...
... 90%+ Success Rate..., CLEARWATER, Fla., Nov. 27 ... announced,today that it has certified over 600 surgeons in ... were trained in the basic technique at the,North American ... "We believe that this milestone is a reasonable ...
Cached Medicine News:Health News:S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias 2Health News:Boiron Laboratories Disputes British Journal's Editorial on Homeopathy 2Health News:Boiron Laboratories Disputes British Journal's Editorial on Homeopathy 3Health News:FDA Panel Backs Tougher Warning for Tamiflu 2Health News:FDA Panel Backs Tougher Warning for Tamiflu 3Health News:Ray Elliott to Retire as Chairman of Zimmer Holdings; John McGoldrick to Serve as Non-Executive Chairman 2Health News:Ray Elliott to Retire as Chairman of Zimmer Holdings; John McGoldrick to Serve as Non-Executive Chairman 3Health News:New Booklet Reveals 12 Proven Methods for Stopping MRSA from Infecting Your Feet and Your Family's Feet 2Health News:Over 600 Surgeons Certified to use TruFUSE(R) to Treat Back Pain Sufferers 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: